目的

探讨乳腺癌患者血清中波形蛋白的表达水平及与各临床病理学特征的关系。

方法

本研究为前瞻性研究。 根据纳入、排除标准,收集2016 年1 ～9 月就诊于解放军兰州总医院的52 例乳腺癌患者和52 例健康女性血清进行研究。 采用ELISA 法检测血清中波形蛋白的表达水平,采用t 检验分析血清波形蛋白在2 组人群中的表达差异,采用单因素方差分析血清波形蛋白在不同分子分型乳腺癌中的表达差异,采用Pearson χ² 检验分析血清波形蛋白表达与各临床病理学特征间的关系。

结果

ELISA 结果显示,乳腺癌患者血清中波形蛋白的表达明显高于健康女性(0.608±0.019 比0.186±0.008,t=19.870, P＜0.001);在不同分子分型乳腺癌中血清波形蛋白的表达不同(F=58.390, P＜0.001),其中luminal A 型乳腺癌为0.487±0.017,luminal B 型为0.557±0.018,HER-2 型为0.767±0.011,三阴性乳腺癌为0.823±0.022;各组两两比较分析可见,luminal B 型、HER-2 型、三阴性乳腺癌中血清波形蛋白的表达均高于luminal A 型(P 均＜0.050),HER-2 型、三阴性乳腺癌中血清波形蛋白的表达均高于luminal B 型(P 均＜0.050),而HER-2 型和三阴性乳腺癌中血清波形蛋白的表达差异无统计学意义(P＞0.050);Pearson χ² 检验结果显示,乳腺癌患者血清中波形蛋白的表达与TNM 分期(χ² =7.989,P=0.005)、淋巴结转移(χ² =5.142,P=0.023)有关,与年龄(χ² =0.349,P=0.554)、肿瘤大小(χ²=0.819,P=0.366)、组织学分级(χ²=0.537,P=0.765)均无关。

结论

波形蛋白在乳腺癌患者血清中高表达,与乳腺癌患者高TNM 分期、淋巴结转移密切相关,有望成为一种新的乳腺癌相关生物学指标。

Objective

To investigate the expression of vimentin in serum of breast cancer patients and its relationship with clinicopathological characteristics.

Methods

It was a prospective study. According to the inclusion and exclusion criteria, totally 52 breast cancer patients and 52 healthy women in the Lanzhou General Hospital of PLA from January 2016 to September 2016 were enrolled. In this study, the expression level of vimentin in serum was detected by ELISA. The difference of serum vimentin expression between two groups was analyzed by the t-test, the expression of serum vimentin among different molecular subtypes of breast cancer was analyzed by one-way ANOVA and the relationship between serum vimentin expression and clinicopathological characteristics was analyzed by Pearson χ² test.

Results

ELISA assay showed that serum vimentin expression in breast cancer patients was significantly higher than that in healthy women (0.608±0.019 vs 0.186±0.008,t=19.870, P＜0.001). Serum vimentin expression was significantly different among different molecular subtypes of breast cancer (luminal A subtype 0.487±0.017, luminal B subtype 0.557±0.018, HER-2 overexpression subtype 0.767±0.011, triple-negative subtype 0.823±0.022; F=58.390, P＜0.001). The pairwise comparison showed that serum vimentin expression in luminal B subtype, HER-2 overexpression subtype or triple-negative subtype was significantly higher than that in luminal A subtype (all P＜0.050), serum vimentin expression in HER-2 overexpression subtype or triple-negative subtype was significantly higher than that in luminal B subtype (both P＜0.050), while there was no significant difference in serum vimentin expression between HER-2 overexpression subtype and triple-negative subtype (both P ＞0.050). Pearson χ² test showed that serum vimentin expression was correlated with TNM stage (χ²=7.989,P=0.005), lymph node metastasis (χ²=5.142, P=0.023), but was not correlated with age (χ²=0.349,P=0.554), tumor size (χ² = 0.819, P = 0.366) and histological grading (χ² = 0.537, P = 0.765).

Conclusion

Vimentin is highly expressed in serum of breast cancer patients and is closely correlated with TNM stage and lymph node metastasis, with the potential as a new biological indicator of breast cancer.